NDA 218592 · Telix
Pixclara
Floretyrosine F-18 · Intravenous
NovelPriority reviewOrphanCDER novel approval, Sep 11, 2026: To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Sep 11, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
2 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 7, 2026.
PIXCLARA is indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older. PIXCLARA is a radioactive diagnostic drug indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older. ( 1 )
Mechanism: Floretyrosine F 18 is a radiolabeled derivative of tyrosine and a substrate for the Large Neutral Amino Acid Transporter 1 and 2 (LAT). LAT is a sodium-independent exchanger protein that transports large neutral amino acids (e.g., tyrosine, phenylalanine) across cell membranes, and it is highly expressed in the blood-brain barrier and glioma tumor tissue. Consequently, floretyrosine F 18 accumulates in cells that express LAT on their surface. Fluorine-18 is a β+ emitting radionuclide that enables positron emission tomography.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 11, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- PIXCLARA · FLORETYROSINE F-18 5-300mCi/ML · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Floretyrosine F-18" as an intervention, any sponsor and status, largest first.
- [18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain MetastasesPivotal-lookingNot yet recruiting
Telix Pharmaceuticals (Innovations) Pty LimitedIndustry
NCT07931261 · 381 participants (planned) · Start Dec 2026 · Primary completion Apr 2028
Drug: Floretyrosine F 18 ([18F]FET) · For: Brain Metastasis; Radiation Necrosis; Pseudoprogression and 1 more
- Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 TrialPivotal-lookingRecruiting
Mayo ClinicAcademic, hospital or other
NCT07935889 · 292 participants (planned) · Start Nov 13, 2026 · Primary completion Nov 30, 2035
Drug: Fluorodopa F 18; Temozolomide · For: Glioblastoma, IDH-Wildtype
Sites: Scottsdale, Arizona; Jacksonville, Florida; Albert Lea, Minnesota · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Telix
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.